NVCT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
7.2M
+15.0%
6.3M
-17.8%
7.6M
-2.3%
7.8M
+18.2%
6.6M
R&D
4.7M
+14.1%
4.1M
-19.3%
5.1M
-11.9%
5.8M
+59.8%
3.6M
SG&A
2.5M
+16.7%
2.2M
-14.9%
2.5M
+25.3%
2.0M
-32.3%
3.0M
Operating Income
-7197000
-15.0%
-6260000
+17.8%
-7617000
+2.3%
-7794000
-18.2%
-6595000
EBITDA
-7197000
-15.0%
-6260000
+17.8%
-7617000
+2.3%
-7794000
-18.2%
-6595000
Net Income
-7020000
-16.0%
-6050000
+17.3%
-7314000
+2.0%
-7462000
-17.8%
-6334000
EPS (Basic)
$-0.30
-15.4%
$-0.26
+16.1%
$-0.31
+29.5%
$-0.44
-46.7%
$-0.30
EPS (Diluted)
$-0.30
-15.4%
$-0.26
+16.1%
$-0.31
+29.5%
$-0.44
-46.7%
$-0.30
Shares (Diluted)
23.5M
+0.3%
23.4M
+0.8%
23.2M
+2.2%
22.7M
+6.3%
21.4M
Nuvectis Pharma (NVCT) โ€” Financials